Overview

* Semler Scientific ( SMLR ) Q2 revenue declines 43% yr/yr, beats analyst expectations, per LSEG data

* Net income for Q2 rises to $66.9 mln, driven by Bitcoin gains

* Company achieves 29% BTC yield in Q2, launches CardioVanta subsidiary during Q2

Outlook

* Company continues to focus on Bitcoin treasury strategy

* Semler Scientific ( SMLR ) emphasizes growth in healthcare via CardioVanta

* Company does not provide specific future financial guidance in its press release

Result Drivers

* BITCOIN STRATEGY - Unrealized gains from Bitcoin holdings significantly boosted net income

* CARDIOVANTA LAUNCH - Launch of CardioVanta subsidiary aims to drive future healthcare initiatives

* INCREASED EXPENSES - Operating expenses rose due to stock-based compensation and legal costs related to U.S. Department of Justice investigation

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $8.22 $8.10

Revenue mln mln (2

Analysts

)

Q2 EPS $5.04

Q2 Basic $5.71

EPS

Q2 -$2.05

Income mln

From

Operatio

ns

Q2 $10.27

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Semler Scientific Inc ( SMLR ) is $98.00, about 64.8% above its August 1 closing price of $34.46

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)